Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124042462 | 12404246 | 2 | F | 201601 | 20160812 | 20160525 | 20160819 | EXP | PL-URPL-S647/2016 | PL-PFIZER INC-2016267298 | PFIZER | 64.00 | YR | F | Y | 57.00000 | KG | 20160819 | MD | PL | PL |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124042462 | 12404246 | 1 | PS | GABAPENTIN. | GABAPENTIN | 1 | Oral | 400 MG, 2X/DAY | U | 20235 | 400 | MG | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124042462 | 12404246 | 1 | Trigeminal neuralgia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124042462 | 12404246 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124042462 | 12404246 | Alanine aminotransferase increased | |
| 124042462 | 12404246 | Angioedema | |
| 124042462 | 12404246 | Aspartate aminotransferase increased | |
| 124042462 | 12404246 | Drug eruption | |
| 124042462 | 12404246 | Eosinophilia | |
| 124042462 | 12404246 | Leukocytosis | |
| 124042462 | 12404246 | Neutrophilia | |
| 124042462 | 12404246 | Product use issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124042462 | 12404246 | 1 | 201512 | 201603 | 0 |